The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients : A Multi-Center Randomized Controlled Trial
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: Our previous study established a 2-dose regimen of high-dose trivalent influenza vaccine (HD-TIV) to be immunogenically superior compared to a 2-dose regimen of standard-dose quadrivalent influenza vaccine (SD-QIV) in pediatric allogeneic hematopoietic cell transplant (HCT) recipients. However, the durability of immunogenicity and the role of time post-HCT at immunization as an effect modifier are unknown.
METHODS: This phase II, multi-center, double-blinded, randomized controlled trial compared HD-TIV to SD-QIV in children 3-17 years old who were 3-35 months post-allogeneic HCT, with each formulation administered twice, 28-42 days apart. Hemagglutination inhibition (HAI) titers were measured at baseline, 28-42 days following each dose, and 138-222 days after the second dose. Using linear mixed effects models, we estimated adjusted geometric mean HAI titer ratios (aGMR: HD-TIV/SD-QIV) to influenza antigens. Early and late periods were defined as 3-5 and 6-35 months post-HCT, respectively.
RESULTS: During 3 influenza seasons (2016-2019), 170 participants were randomized to receive HD-TIV (n = 85) or SD-QIV (n = 85). HAI titers maintained significant elevations above baseline for both vaccine formulations, although the relative immunogenic benefit of HD-TIV to SD-QIV waned during the study. A 2-dose series of HD-TIV administered late post-HCT was associated with higher GMTs compared to the early post-HCT period (late group: A/H1N1 aGMR = 2.16, 95% confidence interval [CI] = [1.14-4.08]; A/H3N2 aGMR = 3.20, 95% CI = [1.60-6.39]; B/Victoria aGMR = 1.91, 95% CI = [1.01-3.60]; early group: A/H1N1 aGMR = 1.03, 95% CI = [0.59-1.80]; A/H3N2 aGMR = 1.23, 95% CI = [0.68-2.25]; B/Victoria aGMR = 1.06, 95% CI = [0.56-2.03]).
CONCLUSIONS: Two doses of HD-TIV were more immunogenic than SD-QIV, especially when administered ≥6 months post-HCT. Both groups maintained higher titers compared to baseline throughout the season.
CLINICAL TRIALS REGISTRATION: NCT02860039.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 78(2024), 1 vom: 25. Jan., Seite 217-226 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schuster, Jennifer E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.01.2024 Date Revised 29.03.2024 published: Print ClinicalTrials.gov: NCT02860039 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciad534 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362940495 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362940495 | ||
| 003 | DE-627 | ||
| 005 | 20240331000711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciad534 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM362940495 | ||
| 035 | |a (NLM)37800415 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schuster, Jennifer E |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients |b A Multi-Center Randomized Controlled Trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT02860039 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Our previous study established a 2-dose regimen of high-dose trivalent influenza vaccine (HD-TIV) to be immunogenically superior compared to a 2-dose regimen of standard-dose quadrivalent influenza vaccine (SD-QIV) in pediatric allogeneic hematopoietic cell transplant (HCT) recipients. However, the durability of immunogenicity and the role of time post-HCT at immunization as an effect modifier are unknown | ||
| 520 | |a METHODS: This phase II, multi-center, double-blinded, randomized controlled trial compared HD-TIV to SD-QIV in children 3-17 years old who were 3-35 months post-allogeneic HCT, with each formulation administered twice, 28-42 days apart. Hemagglutination inhibition (HAI) titers were measured at baseline, 28-42 days following each dose, and 138-222 days after the second dose. Using linear mixed effects models, we estimated adjusted geometric mean HAI titer ratios (aGMR: HD-TIV/SD-QIV) to influenza antigens. Early and late periods were defined as 3-5 and 6-35 months post-HCT, respectively | ||
| 520 | |a RESULTS: During 3 influenza seasons (2016-2019), 170 participants were randomized to receive HD-TIV (n = 85) or SD-QIV (n = 85). HAI titers maintained significant elevations above baseline for both vaccine formulations, although the relative immunogenic benefit of HD-TIV to SD-QIV waned during the study. A 2-dose series of HD-TIV administered late post-HCT was associated with higher GMTs compared to the early post-HCT period (late group: A/H1N1 aGMR = 2.16, 95% confidence interval [CI] = [1.14-4.08]; A/H3N2 aGMR = 3.20, 95% CI = [1.60-6.39]; B/Victoria aGMR = 1.91, 95% CI = [1.01-3.60]; early group: A/H1N1 aGMR = 1.03, 95% CI = [0.59-1.80]; A/H3N2 aGMR = 1.23, 95% CI = [0.68-2.25]; B/Victoria aGMR = 1.06, 95% CI = [0.56-2.03]) | ||
| 520 | |a CONCLUSIONS: Two doses of HD-TIV were more immunogenic than SD-QIV, especially when administered ≥6 months post-HCT. Both groups maintained higher titers compared to baseline throughout the season | ||
| 520 | |a CLINICAL TRIALS REGISTRATION: NCT02860039 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a high dose | |
| 650 | 4 | |a influenza | |
| 650 | 4 | |a pediatrics | |
| 650 | 4 | |a stem cell recipients | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Inactivated |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Hamdan, Lubna |e verfasserin |4 aut | |
| 700 | 1 | |a Dulek, Daniel E |e verfasserin |4 aut | |
| 700 | 1 | |a Kitko, Carrie L |e verfasserin |4 aut | |
| 700 | 1 | |a Batarseh, Einas |e verfasserin |4 aut | |
| 700 | 1 | |a Haddadin, Zaid |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, Laura S |e verfasserin |4 aut | |
| 700 | 1 | |a Stahl, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Potter, Molly |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Herdi |e verfasserin |4 aut | |
| 700 | 1 | |a Kalams, Spyros A |e verfasserin |4 aut | |
| 700 | 1 | |a Bocchini, Claire E |e verfasserin |4 aut | |
| 700 | 1 | |a Moulton, Elizabeth A |e verfasserin |4 aut | |
| 700 | 1 | |a Coffin, Susan E |e verfasserin |4 aut | |
| 700 | 1 | |a Ardura, Monica I |e verfasserin |4 aut | |
| 700 | 1 | |a Wattier, Rachel L |e verfasserin |4 aut | |
| 700 | 1 | |a Maron, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Grimley, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Paulsen, Grant |e verfasserin |4 aut | |
| 700 | 1 | |a Harrison, Christopher J |e verfasserin |4 aut | |
| 700 | 1 | |a Freedman, Jason L |e verfasserin |4 aut | |
| 700 | 1 | |a Carpenter, Paul A |e verfasserin |4 aut | |
| 700 | 1 | |a Englund, Janet A |e verfasserin |4 aut | |
| 700 | 1 | |a Munoz, Flor M |e verfasserin |4 aut | |
| 700 | 1 | |a Danziger-Isakov, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Spieker, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Halasa, Natasha B |e verfasserin |4 aut | |
| 700 | 0 | |a Pediatric HCT Flu Study |e verfasserin |4 aut | |
| 700 | 1 | |a Goyal, Rakesh |e investigator |4 oth | |
| 700 | 1 | |a Thurber, Joanne |e investigator |4 oth | |
| 700 | 1 | |a McHenry, Rendie |e investigator |4 oth | |
| 700 | 1 | |a Bender, Margaret |e investigator |4 oth | |
| 700 | 1 | |a Barto, Shari |e investigator |4 oth | |
| 700 | 1 | |a Russo, Michael |e investigator |4 oth | |
| 700 | 1 | |a Shoemaker, Lauren |e investigator |4 oth | |
| 700 | 1 | |a Truong, Kenny |e investigator |4 oth | |
| 700 | 1 | |a Dvorak, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Allison, Kim J |e investigator |4 oth | |
| 700 | 1 | |a Naik, Swati |e investigator |4 oth | |
| 700 | 1 | |a Williams, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Blum, Samantha |e investigator |4 oth | |
| 700 | 1 | |a Lacombe, Kirsten |e investigator |4 oth | |
| 700 | 1 | |a Smith, Hannah |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 78(2024), 1 vom: 25. Jan., Seite 217-226 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2024 |g number:1 |g day:25 |g month:01 |g pages:217-226 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad534 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2024 |e 1 |b 25 |c 01 |h 217-226 | ||